Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 2 Saturday Friday Sunday Monday Tuesday Publication Only SATURDAY, JUNE 1 ST 9:00am - 12:00pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:00am - 12:00pm Hall A Poster 1535 A unique model: Partnership between community oncology and pharma for clinical trial enrichment. Prakash S Konduri K, Paulson A Care Delivery/Models of Care 9:00am - 12:00pm Hall A Poster 1631 The use of telehealth in a large community oncology practice prior to and during the COVID-19 pandemic. Nickleach D Gordan L Care Delivery/Models of Care 9:00am - 12:00pm Hall A Poster 3113 Targeting rare variants of a pan- cancer target: The landscape of BRAF non-v600 mutations and BRAF fusions from 172,005 adult patients with cancer. Coleman N Subbiah V Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2080 Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT. El-Deiry W Subbiah V Central Nervous System Tumors 9:00am - 12:00pm Hall A Poster 2588 Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study Bermejo Im Wang J, Hamilton E Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2618 Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors. Patel M Patel M, Johnson M Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 3074 Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer Patel M Patel M, Danso M, Cosgrove D, Hamilton E Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 3108 First-in-human phase 1/2a study of the first-in-class, next-generation CDK4- selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/ HER2− mBC Giordano A Williams A, Hamilton E Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 3142 Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Dib E McKean M Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology 9:00am - 12:00pm Hall A Poster 2529 Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors. Falchook G Falchook G, Henry J Developmental Therapeutics— Immunotherapy 9:00am - 12:00pm Hall A Poster 2582 Phase 1/2 study of NGM707, an ILT2/ ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. Wang J Wang J Developmental Therapeutics— Immunotherapy